Market Overview

UPDATE: ISI Group Raises PT to $27 on Hologic Following Guidance Raise

Related HOLX
Hologic Poised on Solid Quarterly Growth Amid Several Odds - Analyst Blog
Hologic's 3D Mammography Improves Breast Cancer Screening - Analyst Blog

ISI Group maintained Hologic (NASDAQ: HOLX) with a Strong Buy rating and raised the price target from $25.50 to $27.00.

ISI Group commented, "Going forward, we expect increased adoption of 3D Tomo (as presaged by the continued sequential backlog increase) and Panther (Diagnostics) to drive growth upside. In the NT, receipt of a potential CMS reimbursement code for 3D Tomo will be a significant catalyst. Given our thesis for a new product cycle accelerating growth, we are reiterating our Strong Buy rating of HOLX shares and raising our price target from $25.50 to $27.00."

Hologic closed at $23.25 on Monday.

Posted-In: ISI GroupAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (HOLX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free

Benzinga Professional